ONO Pharmaceutical Reports 9.4% Drop in Sales and 33% Decrease in Net Profit for Fiscal Year Ended March 2025, EPS Falls to ¥218.02
I'm PortAI, I can summarize articles.
Ono Pharmaceutical Co., Ltd. reported a 9.4% drop in sales to ¥451.8 billion and a 33% decrease in net profit to ¥102.4 billion for the fiscal year ending March 31, 2025. The decline was attributed to reduced drug prices, lower royalty revenue from Merck, and the absence of a previous year's lump-sum income from a patent settlement. Operating profit fell by 39% to ¥114.7 billion, while ordinary profit decreased by 40.3% to ¥112.3 billion, impacted by expenses related to FORXIGA Tablets and licensing agreements.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments